Analysts Set Syndax Pharmaceuticals Inc (SNDX) PT at $16.25

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has been given a consensus rating of “Buy” by the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $18.60.

Several equities research analysts recently commented on the company. Zacks Investment Research cut Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 19th. ValuEngine cut Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, November 26th. Nomura dropped their price objective on Syndax Pharmaceuticals from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday, December 18th. Finally, Morgan Stanley cut Syndax Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $6.00 price objective on the stock. in a research report on Monday, October 29th.

Shares of NASDAQ SNDX traded up $0.71 during trading on Friday, reaching $6.53. The company had a trading volume of 376,270 shares, compared to its average volume of 207,269. Syndax Pharmaceuticals has a 12-month low of $3.39 and a 12-month high of $15.20. The stock has a market cap of $141.81 million, a P/E ratio of -2.25 and a beta of 2.14.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Monday, November 5th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. Syndax Pharmaceuticals had a negative return on equity of 91.11% and a negative net margin of 3,185.75%. The firm had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.38 million. As a group, equities research analysts expect that Syndax Pharmaceuticals will post -2.89 earnings per share for the current year.

A number of large investors have recently made changes to their positions in SNDX. Rhumbline Advisers purchased a new position in Syndax Pharmaceuticals in the second quarter worth about $103,000. Bank of New York Mellon Corp boosted its position in Syndax Pharmaceuticals by 72.9% in the second quarter. Bank of New York Mellon Corp now owns 80,372 shares of the company’s stock worth $564,000 after purchasing an additional 33,892 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Syndax Pharmaceuticals in the second quarter worth about $368,000. BlackRock Inc. boosted its position in Syndax Pharmaceuticals by 30.9% in the second quarter. BlackRock Inc. now owns 1,670,816 shares of the company’s stock worth $11,729,000 after purchasing an additional 394,145 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Syndax Pharmaceuticals by 40.5% in the second quarter. Dimensional Fund Advisors LP now owns 558,725 shares of the company’s stock worth $3,922,000 after purchasing an additional 161,146 shares during the last quarter. 61.75% of the stock is currently owned by institutional investors and hedge funds.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

Read More: What is the NASDAQ Stock Market?

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply